Amendments to the Abstract:

Please replace the abstract with the following rewritten abstract:

This invention relates to 2-arylimino heterocycles, including 2 arylimino 1,3-thiazolidines, 2-arylimino 2,3,4,5-tetrahydro 1,3-thiazines, 2-arylimino 1,3-thiazolidin 4 ones, 2 arylimino 1,3-thiazolidin 5 ones, and 2-arylimino 1,3-oxazolidines, compounds of the formula

$$(T)_{t}R$$
 N
 $R^{1}(G)_{g}$
 $(Q)_{q}R^{2}$
 $(Q)_{q}R^{3}$
 $(C_{n}H_{2n-p})$

B3

wherein R is substituted aryl of 6 - 14 carbons bearing a substituent T, or substituted heteroaryl of 3 - 10 carbons. R¹ is alkyl of 1 - 10 carbons; cycloalkyl of 3 - 12 carbons and containing 1 - 3 rings; heterocycloalkyl of 4 - 7 carbons and containing 1 - 3 rings and 1 - 3 heteroatoms selected from N, O, and S; alkenyl of 2 - 10 carbons; cycloalkenyl of 5 - 12 carbons and containing 1 - 3 rings; or alkynyl of 3 - 10 carbons. R², R³, and R⁴ are independently selected from H; alkyl of 1 - 10 carbons; cycloalkyl of 3 - 12 carbons; alkenyl of 2 - 10 carbons; cycloalkenyl of 5 - 12 carbons; substituted aryl of 6 - 13 carbons; heteroaryl of 3 - 9 carbons and 1-3 heteroatoms selected from N, O and S; CO₂R⁵; halogen; and =O, which represents two of the groups R², R³, and R⁴. X is O. and their use They are used in modulating progesterone receptor mediated processes, for example the treatment of osteoporosis. and pharmaceutical Pharmaceutical compositions for use in such therapies, containing these compounds are also disclosed and claimed.